David Pamies, Marie-Gabrielle Zurich, Thomas Hartung
Highlights
• The high failure in drug development for glioblastoma points to the need for new models
• Organotypic iPSC-derived glioblastoma models (GB-3DBrain) are a valuable novel tool
• Understanding the limitations of GB-3DBrain is necessary for a proper application